Among targeted therapies, protein kinase inhibitors (KIs) are a growing group of drugs used in the majority of cancer indications, including lung, breast, colorectal, kidney, liver, or thyroid cancer, but also melanoma, soft tissue sarcoma, gastrointestinal stroma tumor (GIST), and various hematological malignancies [5,6] New strategies have changed the treatment paradigm in many types of cancer, which are now considered to be chronic diseases rather than fatal diseases with a short life expectancy. Here, UHMK1 is linked to cancer.